# Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)

> **NCT01391611** · PHASE2 · TERMINATED · sponsor: **Kristen Ganjoo** · enrollment: 25 (actual)

## Conditions studied

- Gastrointestinal Stromal Tumor (GIST)

## Interventions

- **DRUG:** Pazopanib

## Key facts

- **NCT ID:** NCT01391611
- **Lead sponsor:** Kristen Ganjoo
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-07
- **Primary completion:** 2013-06
- **Final completion:** 2013-12
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** Lack of efficacy - Futility endpoint reached
- **Last updated:** 2017-04-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01391611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01391611, "Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01391611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*